Last week, AbbVie decided not to exercise that option and forego any rights to bardoxolone, including royalties, whilst also returning its interest in omaveloxolone and other Nrf2 candidates.

NRF2 is associated with tumor recurrence ... BCRF awarded McTiernan $225,000 to continue her investigations into the relationship between exercise and cancer development and progression. McTiernan’s ...